NEW ORLEANS, LA—Among patients with atrial fibrillation (AF) undergoing PCI, 1 month of dual therapy with a direct oral ...
An investigational triple agonist that targets fibroblast growth factor 21, glucagon and GLP-1 receptors cut triglyceride ...
OCEAN was an open-label trial conducted in Australia, Belgium, Canada, China, Germany, and Israel. Eligible participants had ...
For some people with high cholesterol, making lifestyle changes and taking routine cholesterol-lowering statin medications ...
Navar A. Efficacy and safety of enlicitide, an oral PCSK9 inhibitor, for lowering LDL cholesterol in adults with or at-risk for ASCVD: the phase 3 CORALreef lipids trial. Presented at: AHA 2025 ...
The drug targets the PCSK9 protein, and could give millions of people a more affordable option to reduce their heart disease ...
One dose of an experimental drug cover offer lifetime treatment for people with high cholesterol, but its long-term safety is ...
Background: Cardiovascular disease (CVD) prevalence is rising among younger women in the US. Hypertensive disorders of pregnancy (HDP) are early indicators of cardiovascular risk, yet it remains ...
NEW ORLEANS – A single injection of a gene-edited protein was deemed productive and safe in patients with dyslipidemia that ...
In a phase 1 trial, a gene-editing therapy that targets ANGPTL3 was associated with few serious adverse events and at higher ...
The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...
Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback